Bruker AXS and Bruker Optics Introduce D8 SCREENLAB(TM), a Combined XRD and Raman High-Throughput Screening System for Advanced

At Pittcon 2006, Bruker AXS Inc. today launches its new
D8 SCREENLAB(TM), a screening system which combines the analytical
power of two-dimensional X-ray diffraction (XRD2) and Raman
spectroscopy. The D8 SCREENLAB integrates the Bruker AXS D8 DISCOVER
XRD2 system for combinatorial materials screening with the Bruker
Optics Raman probe into one combined advanced materials discovery
solution.
   In the D8 SCREENLAB, the X-ray source, optics and unique 2D X-ray
detector, as well as the laser source, the Raman probe and an
auto-zoomed video microscope are all integrated into one single
platform. As a result, the X-ray diffraction pattern, the Raman
spectrum as well as the optical image from the same sample can be
obtained in one sample run from a materials library. The powerful
PolySNAP(TM) pattern matching software of the D8 SCREENLAB allows the
processing of XRD2 and Raman data, and correlates the analysis
results.
   Professor Chris Frampton, Chief Scientific Officer for Pharmorphix
Ltd., Cambridge, UK, states: "Combinatorial discovery and optimization
methods require rapid screening to evaluate variations of composition,
structure and property within advanced materials libraries. While
X-ray diffraction provides information on the atomic arrangement in
the sample, Raman spectroscopy measures the characteristic vibration
frequencies determined by the chemical bonds. Both X-ray diffraction
and Raman spectroscopy are non-destructive methods that require little
or no sample preparation, thus allowing samples to be analyzed simply
and quickly in their natural form. A combined instrument with both XRD
and Raman capabilities is very beneficial to high-throughput
combinatorial screening in advanced materials and catalyst discovery.
In the pharmaceutical industry, screening based on spectroscopic and
diffraction techniques can be important for drug formulations since
the polymorphism of active ingredients has to be controlled to achieve
reliable product quality which will satisfy regulatory authorities.
The addition of Raman spectroscopy provides even better discrimination
in cases where the X-ray data are ambiguous."
   Dr. Bob He, Director of R&D for Bruker AXS, adds: "Scientists and
engineers from both Bruker AXS and Bruker Optics worked jointly to
integrate the best technologies from the two companies into this
innovative systems solution. With the combination of two analytical
methods, the novel D8 SCREENLAB allows our customers to explore new
opportunities in advanced materials research."
   Pittcon 2006, the 57th Pittsburgh Conference and Exposition on
Analytical Chemistry and Applied Spectroscopy, is being held March
13-16 in Orlando, Florida in the Orange County Convention Center. The
D8 SCREENLAB will be exhibited at the Bruker AXS booth, #3155.

   ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

   Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker
Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer
and provider of life science, materials research and industrial X-ray
analysis tools. Bruker Daltonics is a leading developer and provider
of innovative life science tools based on mass spectrometry. Bruker
Daltonics also offers a broad line of nuclear, biological and chemical
(NBC) detection products for defense and homeland security. For more
information, please visit www.bruker-biosciences.com

   ABOUT BRUKER OPTICS

   Bruker Optics Inc is a privately held company, which manufactures
and distributes analytical and process analysis instruments based on
infrared, near-infrared, Raman and TD-NMR spectroscopy. These products
are utilized in industry, government and academia for a wide range of
applications, such as chemical, polymer, forensic, and
pharmaceuticals. The company is based in Billerica, Massachusetts and
has manufacturing facilities in Ettlingen, Germany and The Woodlands,
Texas. For more information, please visit http://www.brukeroptics.com

   CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the Company's products, exposure to currency
fluctuations, changes in governmental regulations, capital spending
and government funding policies, FDA and other regulatory approvals to
the extent applicable, competition, the intellectual property of
others, patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the SEC,
including, without limitation, our respective annual reports on Form
10-K, our most recent quarterly reports on Form 10-Q, and our current
reports on Form 8-K. We disclaim any intent or obligation to update
these forward-looking statements.